Image de couverture de livre

The use of different types of networks, alone and in combination, for drug target identification

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteur principal:	Paolo Parini
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	British Journal of Pharmacology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Artificial intelligence streamlines scientific discovery of drug–target interactions
par: Yuxin Yang, et autres
Publié: (2025)

A computer‐aided drug repurposing: the antibacterial agents targeting GroEL
par: Dongdong Zhang, et autres
Publié: (2025)

Validating use of diagnostic codes in Canadian administrative data for identification of adverse drug events
par: Maeve E. Wickham, et autres
Publié: (2024)

Systematic drug screening and target analysis identify digitoxin as a potential therapy for uveal melanoma
par: Huilin Liu, et autres
Publié: (2024)

Circumventing glioblastoma resistance to temozolomide through optimal drug combinations designed by systems pharmacology and machine learning
par: Sergio Corridore, et autres
Publié: (2025)

System level network data and models attack cancer drug resistance
par: Márk Kerestély, et autres
Publié: (2025)

EpigenPlot: An interactive web platform for DNA methylation‐based biomarker and drug target discovery in colorectal cancer
par: Dalma Müller, et autres
Publié: (2025)

Non‐canonical nitric oxide signalling and DNA methylation: Inflammation induced epigenetic alterations and potential drug targets
par: Christopher H. Switzer
Publié: (2024)

TNMplot: An enhanced platform for pharmacological target identification through cross‐stage and pan‐cancer gene expression analysis
par: Áron Bartha, et autres
Publié: (2026)

Single‐dose and steady‐state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug–drug interaction study
par: Amelie Leutzendorff, et autres
Publié: (2024)

Exploring the link between antihypertensive drugs targets and pancreatitis risk through Mendelian randomization
par: Zhiwei Du, et autres
Publié: (2025)

Lack of clinically significant drug–drug interactions between the third‐generation integrase strand transfer inhibitor VH4524184 (VH‐184) and combined oral contraceptives
par: E. Doyle, et autres
Publié: (2025)

Effects of vaccines targeting interleukin‐1 receptor, type I on atrial and ventricular function after myocardial infarction
par: Jianwu Huang, et autres
Publié: (2026)

Targeted peptide‐modified M2 exosomes drug delivery system for the targeted regulation of the lung injury microenvironment with isorhynchophylline (IRN): based on the inflammatory–metabolic–epigenetic synergy mechanism
par: Jin‐Ru Zou, et autres
Publié: (2026)

Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties
par: Geofrey Oteng Phutietsile, et autres
Publié: (2024)

Advancing antihypertensive drug development
par: Fay Pu, et autres
Publié: (2025)

Predicting drug–drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling
Publié: (2024)

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing
par: Simon K. Wellenberg, et autres
Publié: (2025)

Pharmacokinetic modelling to enable early attrition of repurposed antiviral drug combination candidates with a high likelihood of failure in COVID‐19
Publié: (2024)

Sex differences in the vasoactive effect of transient receptor potential channels: TRPM3 as a new therapeutic target for (neuro)vascular disorders
par: Eduardo Rivera‐Mancilla, et autres
Publié: (2025)

Opportunities of patient‐derived organoids in drug development
par: Antonia Büning, et autres
Publié: (2025)

Genetic polymorphisms influencing antihypertensive drug responses
par: Jana El Cheikh, et autres
Publié: (2024)

Chemistry/structural biology of psychedelic drugs and their receptor(s)
par: Ryan H. Gumpper, et autres
Publié: (2024)

Emerging therapeutic opportunities for psychedelic and related drugs
par: Susan Wonnacott, et autres
Publié: (2026)

Evaluating the capability of ChatGPT in predicting drug–drug interactions: Real‐world evidence using hospitalized patient data
par: Ramya Padmavathy Radha Krishnan, et autres
Publié: (2024)

Repurposing SGLT2 and DPP‐4 inhibitors for mild cognitive impairment in type 2 diabetes mellitus: Insights from proteomics, target prediction and molecular docking
par: Shams T. Osman, et autres
Publié: (2026)

Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus
par: Julia Kopanz, et autres
Publié: (2025)

Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy
par: Rita Nogueiras‐Álvarez, et autres
Publié: (2024)

Correction to “Genetic polymorphisms influencing antihypertensive drug responses”
Publié: (2025)

The eyes of the beholder: Perceived barriers to successful drug repurposing
par: Zsuzsanna Ida Petykó, et autres
Publié: (2025)

Exploring drug mechanisms through single‐cell proteomics
par: Yuzhi Sun, et autres
Publié: (2026)

Recent innovations in targeting redox biology for therapeutics
par: Miriam M. Cortese‐Krott, et autres
Publié: (2025)

Cancer pain: current practice and emerging targets
par: Yi Ye, et autres
Publié: (2026)

Variable temocillin protein binding and pharmacokinetics in different clinical conditions: Implications for target attainment
par: Letao Li, et autres
Publié: (2025)

Natural products and cancer: From drug discovery to prevention and therapy
par: Angelo A. Izzo, et autres
Publié: (2025)

Identification of drug repurposing candidates for the treatment of polycystic kidney disease
par: Alina Meyer, et autres
Publié: (2026)

Monocytic microRNAs—Novel targets in atherosclerosis therapy
par: Gerhild Euler, et autres
Publié: (2024)

Protein tyrosine phosphatases as emerging targets for cancer immunotherapy
par: Zihan Qu, et autres
Publié: (2024)

Network medicine and systems pharmacology approaches to predicting adverse drug effects
par: Alessio Funari, et autres
Publié: (2024)

Galangin alleviates vitiligo by targeting ANXA2 degradation in macrophages
par: Wenjing Wei, et autres
Publié: (2025)